Immix Biopharma, Inc.
IMMX · XNASCIK 1873835fmd_13S2CQKW098QM8QCDFWMH61JQPManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 24 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Research and development | 0 | 0 | 4 | 9 | 11 | 16 |
| Total operating expenses | 0 | 1 | 8 | 16 | 23 | 30 |
| Operating income | (0) | (1) | (8) | (16) | (23) | (30) |
| Interest expense | 0 | 0 | 0 | – | – | – |
| Interest and investment income | – | – | – | 1 | 1 | 1 |
| Other non-operating income (expense) | (1) | (23) | (0) | 1 | 1 | 1 |
| Income before taxes | (1) | (24) | (8) | (16) | (22) | (29) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (1) | (24) | (8) | (16) | (22) | (29) |
| Net income | (1) | (24) | (8) | (15) | (22) | (29) |